IMPURITIES AVAILABLE FOR 'Zanubrutinib'

Omsynth Lifesciences Pvt. Ltd. is one of the leading manufacturer and exporter of Zanubrutinib. Zanubrutinib is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor used for the treatment of various B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström macroglobulinemia. It works by irreversibly binding to BTK, thereby blocking B-cell receptor signaling and inhibiting the growth and survival of malignant B cells. Zanubrutinib is administered orally and demonstrates high BTK occupancy with improved selectivity compared to first-generation BTK inhibitors. It has favorable pharmacokinetic properties and provides sustained therapeutic activity. The drug is effective in patients with relapsed or refractory hematologic cancers and has shown durable clinical responses. Common adverse effects include neutropenia, upper respiratory tract infections, bruising, diarrhea, and fatigue. Patients receiving Zanubrutinib should be monitored for bleeding, infections, and cardiac events, including atrial fibrillation. Zanubrutinib should be used under the supervision of a qualified healthcare professional according to approved treatment guidelines. Buy high quality Zanubrutinib from Omsynth Lifesciences.